

1 **Supplemental Information**

2
3 **Different resource allocation in a bimodal *Bacillus subtilis* population**
4 **displaying bimodal motility**
5

6
7 Simon Syvertsson, Biwen Wang, Jojet Staal, Yongqiang Gao, Remco Kort, Leendert
8 W. Hamoen
9

10 Table of content

- 11 • Strain construction
- 12 • RNA extraction and RNA-seq analysis
- 13 • Table S1: Strains used in this study
- 14 • Table S2: Plasmids used in this study
- 15 • Table S3: Oligonucleotides used in this study
- 16 • Fig. S1: Effect of blocking *rpsD* autoregulation on cellular expression.
- 17 • Fig. S2: q-RT-PCR of *rpsJ*, *rplC* and *rpsD* mRNA in wild type and $\Delta sigD$ cells.
- 18 • References

19 **Strain construction**

20 Strains, plasmids and oligonucleotides used are listed in Table S1, S2 and S3,
21 respectively. Strain bSS339, containing the *Phag-gfp* reporter was constructed by
22 transforming chromosomal DNA from DS901 to wild type background 168CA.

23 The *gfp-ssrA* vector plasmid pSS52 was created by cutting pSG1164 with *SpeI*,
24 blunting the ends with Klenow fragment, then cutting again with *BsrGI* (which cuts
25 in the middle of *gfp*). An insert was created by amplifying *gfp* from pSG1164 using
26 primer pair oSS63/oSS106, carrying an *ssrA* overhang. The insert was cut with *BsrGI*
27 and ligated blunt/sticky ends into the vector. An IPTG-inducible *Phyper-hy-gfp-ssrA*
28 construct was created with vector plasmid pDR111 using *HindIII* and *SphI*. A *gfp-*
29 *ssrA* insert was amplified from pSS52 using primer pair oSS159/oSS158, and a *gfp*
30 insert was amplified from pSG1164 (oSS159/oSS160). *gfp-ssrA* and *gfp* were ligated
31 into pDR111, creating pSS59 and pSS60, respectively.

32 To create versions of the *gfp-ssrA* construct carrying weaker versions of *ssrA*,
33 pSS59 was mutagenized using PCR with the linearizing primer pairs oSS173/oSS174
34 or oSS175/oSS176 to create mutations 'DAV' and 'AAV', respectively (plasmids
35 pSS67 and pSS68, respectively). The PCR product was treated with *DpnI* and purified
36 using a PCR clean up kit to remove template product. The linearized plasmid was
37 kinated using T4 PNK, then ligated using T4 DNA Ligase (Roche), before being
38 transformed into competent DH5a *E. coli*.

39 The *PrpsD-gfp-ssrA* reporter plasmid pSS102 for integration at the *amyE* locus
40 was created using CloneJet (Thermo Scientific). 550 bp PCR products of the 3' and 5'
41 ends of *amyE* were amplified using primer pairs oSS243/oSS244 and
42 oSS251/oSS252, respectively. A spectinomycin resistance cassette was amplified

43 from pSG1154 using oSS245/oSS246, a 333 bp region of *PrpsD* extending until the
44 start codon of *rpsD*, from 168CA chromosomal DNA using oSS247/oSS248. *sfGFP*
45 was amplified from pSG1729-sfGFP using oSS249/oSS250, with oSS250 providing
46 part of the SsrA tag in a non-complementary overhang sequence. Using overlap
47 extension PCR, the fragments were joined in the following order: *amyE* 5', *spcR*,
48 *PrpsD*, *sfGFP-ssrA*, *amyE* 3', and joined using the terminal primer pair
49 oSS243/oSS252. The resulting 3.3 kbp fragment was cloned into PJET1.2Blunt using
50 the protocol and T4 DNA ligase provided by the supplier, then transformed into DH5a
51 *E. coli*. A *PrpsD-gfp* reporter construct (lacking *ssrA*) was created from pSS102 by
52 linearizing the plasmid with primer pair oSS190/oSS429 by PCR. The linearized
53 plasmid was treated with *DpnI*, PNK and ligase as described above, resulting in
54 plasmid pSS164. The SsrA tag variants 'DAV' and 'AAV' were constructed using
55 primer pairs oSS424/oSS425 and oSS424/oSS426, respectively, and plasmid pSS102
56 as template, resulting in integration vectors plasmids pSS160 and pSS161,
57 respectively.

58 A *Phag-mCherry* reporter construct was made based on the *Phag-gfp* construct
59 from (1). A 377 bp *Phag* fragment was amplified from 168CA chDNA using primers
60 oSS411/oSS370, and a 749 bp *mCherry* fragment from DS1675 chDNA using primers
61 oSS412/oSS413. The promoter and reporter were joined by overlap extension PCR
62 using 1 µl of each purified fragment as template, and oSS370/oSS413 as primers.
63 The resulting 1103 bp *Phag-mCherry* fragment was cut using *EcoRI* and ligated into
64 pAPNC213Cat linearized using the same enzyme and treated with calf intestine
65 alkaline phosphatase (Roche), resulting in pSS153.

66 To block autoregulation of *rpsD* expression, the S4 binding region between +21

67 to +156 was removed using primers oSS332/oSS333 from pSS102, resulting in
68 integration vector pSS114, after digestion of the PCR product with *Bam*HI and self-
69 ligation.

70 *B. subtilis* strains containing the different recombined plasmids and deletions
71 were constructed using standard protocols for inducing natural competence (2).

72

73 **RNA extraction and RNA-seq analysis**

74 Total RNA extraction was performed according to (3). Briefly, cell pellets were
75 resuspended in 0.4 ml ice-cold PBS and added to a screw cap tube containing 1.5 g
76 glass beads (0.1 mm), 0.4 ml 25:24:1 phenol/chloroform/isoamyl alcohol mixture
77 (P/C/I) and 50 µl 10 % SDS, followed by vortexing to mix the suspension thoroughly.
78 Cell disruption was achieved by bead beating (Precellys 24). After centrifugation, the
79 RNA in the upper aqueous phase was ethanol-precipitated, washed twice with 70 %
80 ethanol, dried and dissolved in water. DNA was removed by DNaseI (New England
81 Biolabs) treatment. RNA was then extracted by a second-round of P/C/I cleaning,
82 followed by ethanol-precipitation and washing. After dissolving the RNA pellet in
83 water, the concentration was measured using Qubit™ RNA HS Assay Kit
84 (Invitrogen™).

85 In order to better quantifying the abundance of transcripts in the GFP-on/off
86 cells, we made use of External RNA Controls Consortium (ERCC) synthesized control
87 RNAs as internal ruler. Briefly, 1 µl 1:1000 diluted ERCC RNA Spike-In mix 1
88 (Invitrogen) was added to 50 ng RNA sample and mixed thoroughly. The mixed RNA
89 was subjected to sequencing library construction using the NEBNext® Ultra™ II
90 Directional RNA Library Prep Kit for Illumina® (New England Biolabs), according to

91 the manufacturer's instructions. As control, RNA of unsorted bSS339 cells was also
92 mixed with ERCC RNA and sequenced. Importantly, all libraries with the ERCC spike-
93 in controls have undergone 9 PCR-amplification cycles. The libraries were sequenced
94 by Illumina NextSeq 550 System using NextSeq 500/550 High Output v2.5 kit (75-
95 bp read length), and the raw data were analyzed on the web-based platform Galaxy.
96 Reads of different libraries were firstly normalized based on sequencing depth, then
97 the total reads of ERCC spike-in control RNAs in each library were calculated and
98 used to further normalize the transcripts in respective libraries. After ERCC
99 normalization, the reads of each genes were compared between the GFP-on and the
100 GFP-off libraries. An Excel file of the results is available in the supplementary
101 information.

102

103 Table S1. Strains used in this study. *Spc*, *cat* and *tet* refers to spectinomycin,
 104 chloramphenicol and tetracycline resistance cassettes, respectively.

Strain	Genotype	Construction or reference
168CA	<i>trpC2</i> wild-type <i>B. subtilis</i>	Laboratory strain
CB100	<i>sigD::cat</i>	(4)
DS901	PY79 <i>amyE::(Phag-gfp cat)</i>	(1)
bSS135	168CA <i>amyE::Pspac(hy)-gfp-ssrA spc</i>	168CA x pSS59
bSS136	168CA <i>amyE::Pspac(hy)-gfp spc</i>	168CA x pSS60
bSS161	168CA <i>amyE::Pspac(hy)-gfp-ssrADAV spc</i>	168CA x pSS67
bSS162	168CA <i>amyE::Pspac(hy)-gfp-ssrAAAV spc</i>	168CA x pSS68
bSS277	168CA <i>amyE::PrpsD-sfGFP-ssrA spc</i>	168CA x pSS102
bSS322	168CA <i>amyE::(PrpsDΔ(21-156)-sfGFP-ssrA spc)</i>	168CA x pSS114
bSS385	168CA <i>aprE::Phag-mCherry cat</i>	168CA x pSS153
bSS387	168CA <i>amyE::PrpsD-sfGFP-ssrA spc aprE::Phag-mCherry cat</i>	bSS277 x bSS385
bSS410	168CA <i>amyE::PrpsD-sfGFP-ssrAAAV spc</i>	168CA x pSS161
bSS411	168CA <i>amyE::PrpsD-sfGFP-ssrADAV spc</i>	168CA x pSS160
bSS421	168CA <i>amyE::PrpsD-sfGFP spc</i>	168CA x pSS164
bSS429	168CA <i>amyE::PrpsD-sfGFP spc aprE::Phag-mCherry cat</i>	bSS421 x bSS385
bSS432	168CA <i>amyE::PrpsD-sfGFP-ssrAAAV spc aprE::Phag-mCherry cat</i>	bSS385 x bSS410
bSS485	168CA <i>amyE::Pspac(hy)-gfp-ssrA spc clpX ::cat</i>	bSS135 x JK47
bSS492	168CA <i>amyE::PrpsD-sfGFP-ssrADAV spc aprE::Phag-mCherry cat</i>	bSS385 x bSS411
bSS339	168CA <i>amyE::Phag-gfp cat</i>	168CA x DS901
bSS407	168CA <i>amyE::PrpsD-sfGFP-ssrA spc aprE::Phag-mCherry tet sigD::cat</i>	bSS407 x CB100

105

106 Table S2: Plasmids used in this study

plasmid	Genotype	reference
pDR111	<i>amyE::(Phyper-spank lacI spc) bla</i>	(5)
pSG1164	<i>Pxyl-gfpmut1 bla cat</i>	(6)
pSG1154	<i>amyE::(Pxyl-MCS-gfp spc) bla</i>	(7)
pJet1.2/blunt	<i>bla rep placUV 5-eco47IR' (blunt) 'eco47IR</i>	GenBank: EF694056
pSG1729-sfGFP	<i>amyE::(sfGFP spc) bla</i>	F. Bürmann, unpublished
pAPNC213Cat	<i>aprE::(MCS lacI cat) bla</i>	(8)
pSS52	<i>amyE::(gfp-ssrA spc) bla</i>	this work
pSS59	<i>amyE::(Phyper-spank-gfp-ssrA spc) bla</i>	this work
pSS60	<i>amyE::(Phyper-spank-gfp spc) bla</i>	this work
pSS67	<i>amyE::(Phyper-spank-gfp-ssrADAV spc) bla</i>	this work
pSS68	<i>amyE::(Phyper-spank-gfp-ssrAAAV spc) bla</i>	this work
pSS102	<i>amyE::(PrpsD-sfGFP-ssrA spc) bla</i>	this work
pSS114	<i>amyE::(PrpsDΔ(21-156)-sfGFP-ssrA spc) bla</i>	this work
pSS153	<i>aprE::(Phag-mCherry cat) bla</i>	this work
pSS160	<i>amyE::(PrpsD-sfGFP-ssrADAV spc) bla</i>	this work
pSS161	<i>amyE::(PrpsD-sfGFP-ssrAAAV spc) bla</i>	this work
pSS164	<i>amyE::(PrpsD-sfGFP spc) bla</i>	this work


107

108 Table S3: Oligonucleotides used in this study.

Olig name	Sequence (5' to 3') (CAPITALS = complementary)
oSS63	GAATTCCTGCAGATGAGTAAAGG
oSS106	gcgcgcaagcttgcgcttaggcagctaatactgctacgttttggttaaaactgtagttttgcccgcgatctTTTGTATAG TTCATCCATGCC
oSS158	gcgccgcatgcGCGCTTAGGCAGCTAATGC
oSS159	gcgcgcaagcttTAAGGAGGCCTGCAGATGAGTAAAGGAG
oSS160	gcgccgcatgcAGTGGATCTGAAGTCTGGAC
oSS173	CCACCGAATTAGCTTGCATGCGCGCTTAaaCAGCgtcTGCTACGTTTTGGTTAAAAGTGT
oSS174	AACAGTTTTAACCAAAACGTAGCAgacGCTGttTAAGCGCGCATGCAAGCTAATTCGGTGG
oSS175	CCACCGAATTAGCTTGCATGCGCGCTTAaaCAGCggcTGCTACGTTTTGGTTAAAAGTGT
oSS176	AACAGTTTTAACCAAAACGTAGCAgaccGCTGttTAAGCGCGCATGCAAGCTAATTCGGTGG
oSS190	ATTCTGCGTGACATCCCATC
oSS243	GTCTAGCCTTGCCCTCAATG
oSS244	gattaataattACTGACGATTACCTTGCGTG
oSS245	gtaatcgtcagTAATTATTAATCTGTAGACAAATTGTG
oSS246	GATAAAAACATGGTCTTTGAAGCATGCAAATGTCAC
oSS247	gctcaaagACCATGTTTTTATCACCTAAAAG
oSS248	ctttgctcatcgcaggaattccATAATGTGACTCCTCCTTTG
oSS249	gaattCCTGCAGATGAGCAAAGGAGAAGAAGACTTTTC
oSS250	ctaactgctacgttttggttaaaactgtagttttgcccgTTTTGTAGAGCTCATCCATGC
oSS251	gttttaacaaaacgtagcattagctgcctaataaGTGTATTTTGTGTATTCCAGTC
oSS252	ATGTTTGCAAACGATTCAAAC
oSS332	gcgcgatccAAGGCTGCAATATTTACAC
oSS333	gcgcgatccAATAAAACCAAAGGAGGAGTC
oSS370	cgcggaattcTTATCGCGGAAAATAAACGAAG
oSS411	gtagttcctcctatgtgctagcGAATATGTTGTTAAGGCACGTC
oSS412	GCTAGCACATAAGGAGGAACTACTATGGTCAGCAAGGGAGAGG
oSS413	gcgcggaattcATCCTTATTTGTATAATTCGTCC
oSS424	TGCTACGTTTTGGTTAAAAGTGT
oSS425	gacGCTGttTAATAAGTGTATTTTGTGTATTCC
oSS426	gccGCTGttTAATAAGTGTATTTTGTGTATTCC
oSS429	tcattaTTTGTAGAGCTCATCCATGCC
	q-RT-PCR primers
GapA-Fw	ATTGGACGTAACGTATTCCGCG
GapA-Rv	CTTCAGCGTCTAATTTTCCGTGTA
rpsJ-Fw	GGTCCGATTCCGTTGCCAACTG
rpsJ-Rv	TGTGGTGTGGGTTACAATGTCCG
rplC-Fw	GCGCTTCGTTAAAGAATTACGCGGA
rplC-Rv	GATCGCACCTTGGAACCTTTACCT

109


110 Fig. S1



111

112 Fig. S1: Effect of blocking *rpsD* autoregulation on cellular expression. The *rpsD*
113 promoter, lacking the binding site for ribosomal protein S4 binding (region +21 to
114 +156) was fused to *gfp-ssrA* (strain bSS399, which also contains the *Phag-mCherry*
115 reporter fusion). This prevents autoregulation of expression by the product of *rpsD*,
116 which is ribosomal protein S4 (9). Cells were grown in CH medium at 37 °C and
117 sampled after 60 min in exponential growth. (A) Phase contrast, GFP and mCherry
118 (RFP) signals. Scale bar is 5 μ m. (B) Scatter-histogram plots of *PrpsD-gfp-ssrA* (GFP)
119 and *Phag-mCherry* (RFP) activities of 887 cells.

120 Fig. S2



121

122 Fig. S2: q-RT-PCR of *rpsJ*, *rplC* and *rpsD* mRNA in wild type and $\Delta sigD$ cells. Cultures
123 were sampled from an exponentially growing culture at 1 hr and 2 hr, corresponding
124 to the first two time points of Fig. 5. Averages are based on 5 biological replicates.

125

126 **References**

- 127 1. Kearns DB, Losick R. 2005. Cell population heterogeneity during growth of
128 *Bacillus subtilis*. *Genes Dev* 19:3083-94.
- 129 2. Anagnostopoulos C, Spizizen J. 1961. Requirements for transformation in
130 *Bacillus subtilis*. *J Bacteriol* 81:741-746.
- 131 3. Hamoen LW, Smits WK, de Jong A, Holsappel S, Kuipers OP. 2002. Improving
132 the predictive value of the competence transcription factor (ComK) binding site
133 in *Bacillus subtilis* using a genomic approach. *Nucleic Acids Res* 30:5517-28.
- 134 4. Mirel DB, Lauer P, Chamberlin MJ. 1994. Identification of flagellar synthesis
135 regulatory and structural genes in a sigma D-dependent operon of *Bacillus*
136 *subtilis*. *J Bacteriol* 176:4492-500.
- 137 5. Britton RA, Eichenberger P, Gonzalez-Pastor JE, Fawcett P, Monson R, Losick R,
138 Grossman AD. 2002. Genome-wide analysis of the stationary-phase sigma
139 factor (sigma-H) regulon of *Bacillus subtilis*. *J Bacteriol* 184:4881-90.
- 140 6. Lewis PJ, Marston AL. 1999. GFP vectors for controlled expression and dual
141 labelling of protein fusions in *Bacillus subtilis*. *Gene* 227:101-10.
- 142 7. Feucht A, Lewis PJ. 2001. Improved plasmid vectors for the production of
143 multiple fluorescent protein fusions in *Bacillus subtilis*. *Gene* 264:289-97.
- 144 8. Morimoto T, Loh PC, Hirai T, Asai K, Kobayashi K, Moriya S, Ogasawara N. 2002.
145 Six GTP-binding proteins of the Era/Obg family are essential for cell growth in
146 *Bacillus subtilis*. *Microbiology* 148:3539-52.
- 147 9. Grundy FJ, Henkin TM. 1992. Characterization of the *Bacillus subtilis rpsD*
148 regulatory target site. *J Bacteriol* 174:6763-70.
- 149